Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression

Acta Oncologica

Volumn 52, Issue 3, 2013, Pages 492-497

  Kil, Whoon Jong ^a   Nichols, Romaine C ^a   Hoppe, Bradford S ^a   Morris, Christopher G ^a   Marcus, Robert B ^a   Mendenhall, William ^a   Mendenhall, Nancy P ^a   Li, Zuofeng ^a   Costa, Joseph A ^b   Williams, Christopher R ^b   Henderson, Randal H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; TESTOSTERONE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; CANCER SIZE; RADIATION SCATTERING; SEMINAL VESICLE;

EID: 84875141809     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.767983     Document Type: Article

References (30)

1. Brenner D J , Hall E J. Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 1999 ; 43 : 1095-1101.
2. Duchesne GM , Peters LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1999 ; 44 : 747-8.
3. Brenner D J. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2000 ; 48 : 315-6.
4. Kupelian P A , Reddy C A , Klein EA , Willoughby T R. Shortcourse intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001 ; 51 : 988-93.
5. Kupelian PA , Reddy CA , Carlson T P , Altsman KA , Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity- modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002 ; 53 : 904-12.
6. Zagars GK , P ollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1997 ; 39 : 85-9.
7. Segal R J , Reid R D , Courneya K S , Sigal R J , Kenny G P , Prud'Homme DG , et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009 ; 27 : 344-51.
8. Pickles T , Graham P. What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol 2002 ; 167 : 2448-52.
9. Tomic R , Bergman B, Damber JE , Littbrand B , Lofroth PO. Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin. J Urol 1983 ; 130 : 287-9.
10. Oermann E K , Suy S , Hanscom H N , Kim J S , Lei S , Yu X , et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol. 2011 ; 4 : 12.
11. Mendenhall NP , Li Z, Hoppe BS , Marcus RB , Jr., Mendenhall WM , Nichols RC , et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012 ; 82 : 213-21.
12. Coen J J, Paly J J, Niemierko A , Weyman E , Rodrigues A , Shipley WU , et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012 ; 82 : e201-9.
13. Yoon M , Ahn SH, Kim J, Shin DH, Park SY , Lee SB, et al. Radiation-induced cancers from modern radiotherapy techniques: Intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol Phys 2010 ; 77 : 1477-85.
14. Nichols RC, Jr., Morris CG, Hoppe BS, Henderson RH, Marcus RB , Jr., Mendenhall WM , et al. Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression. Int J Radiat Oncol Biol Phys 2012 ; 82 : 1222-6.
15. Daniell HW, Clark JC , Pereira SE , Niazi ZA , Ferguson DW , Dunn SR , et al. Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer 2001 ; 91 : 1889-95.
16. Yoon FH, Perera F , Fisher B , Stitt L. Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients. Int J Radiat Oncol Biol Phys 2009 ; 74 : 1186-90.
17. Yau I , Vuong T , Garant A , Ducruet T , Doran P , Faria S , et al. Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer. Int J Radiat Oncol Biol Phys 2009 ; 74 : 1481-6.
18. Seal U S. FSH and LH elevation after radiation for treatment of cancer of the prostate. Invest Urol 1979 ; 16 : 278-80.
19. Grigsby PW , Perez CA. The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J Urol 1986 ; 135 : 726-7.
20. Boehmer D , Badakhshi H , Kuschke W , Bohsung J , Budach V. Testicular dose in prostate cancer radiotherapy: Impact on impairment of fertility and hormonal function. Strahlenther Onkol 2005 ; 181 : 179-84.
21. King CR , Maxim PG , Hsu A , Kapp DS. Incidental testicular irradiation from prostate IMRT: It all adds up. Int J Radiat Oncol Biol Phys 2010 ; 77 : 484-9.
22. Mydlo JH, Lebed B. Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men? Scand J Urol Nephrol 2004 ; 38 : 221-4.
23. Taira AV , Merrick G S , Galbreath R W , Butler W M , Lief J H, Allen ZA , et al. Serum testosterone kinetics after brachytherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012 ; 82 : e33-8.
24. Izard MA. Leydig cell function and radiation: A review of the literature. Radiother Oncol 1995 ; 34 : 1-8.
25. Rowley M J , Leach D R , Warner G A , Heller C G. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974 ; 59 : 665-78.
26. Shapiro E, Kinsella T J , Makuch RW , Fraass BA , Glatstein E , Rosenberg SA , et al. Effects of fractionated irradiation of endocrine aspects of testicular function. J Clin Oncol 1985 ; 3 : 1232-9.
27. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006 ; 65 : 1-7.
28. Paganetti H, Bortfeld T , Delaney T F. Neutron dose in proton radiation therapy: In regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;65:1-7). Int J Radiat Oncol Biol Phys 2006 ; 66 : 1594-5 ; author reply 5.
29. Shin D , Yoon M , Kwak J, Shin J, Lee SB , Park SY , et al. Secondary neutron doses for several beam confi gurations for proton therapy. Int J Radiat Oncol Biol Phys 2009 ; 74 : 260-5.
30. Mesoloras G , Sandison GA , Stewart RD , Farr JB, Hsi WC. Neutron scattered dose equivalent to a fetus from proton radiotherapy of the mother. Med Phys 2006 ; 33 : 2479-90.